EBITDA flat but NZD 136.6m impairment collapse drove NPAT to -NZD 144.2m

What changed

Revenue grew 3.3% to NZD 99.1m, broadly continuing the mid-single-digit growth trajectory from prior periods. EBITDA was effectively flat, slipping NZD 0.5m to NZD 28.7m — a margin compression signal even before the impairment.

The dominant movement is the operating profit collapse, from NZD 2.4m to -NZD 133.9m, driven by an impairment charge that sits between the EBITDA line and operating profit. PBT fell to -NZD 136.6m from -NZD 0.1m, and NPAT landed at -NZD 144.2m versus -NZD 1.5m in HY25. These headline losses are substantially explained by the impairment; underlying operating cash generation moved in the opposite direction.

Operating cash flow rose 48.6% to NZD 25.7m, and free cash flow (to the firm) improved to NZD 6.2m from NZD 0.1m. Gross borrowings fell to NZD 23.2m from NZD 36.7m, cutting net debt to approximately NZD 7.7m and net debt/EBITDA to 0.3x from 0.9x. Total assets contracted NZD 127.1m to NZD 316.7m and equity fell NZD 125.0m to NZD 186.8m, both largely reflecting the impairment write-down.

Segment mix shifted modestly toward New Zealand (now 39.3% of group revenue at ~68% EBITDA margin), while North America declined slightly to NZD 39.3m and compressed its EBITDA margin to approximately 23.4% from approximately 25.7% in HY25. Australia continued to scale, with revenue up to NZD 8.2m from NZD 6.5m and EBITDA margin around 45%. No dividend was declared.

What matters

1. The impairment charge, not operations, drove the result. The gap between flat EBITDA (NZD 28.7m) and deeply negative operating profit (-NZD 133.9m) is approximately NZD 162.6m — the impairment charge embedded in the period. This is a non-cash write-down that recalibrates the book value of assets (most likely goodwill associated with North America or the broader platform) rather than reflecting a deterioration in trading cash flows. The practical effect is a NZD 125m reduction in equity and material ROE distortion (-77.2%). Investors need the impairment disclosure — specifically what assets were written down, why, and whether the carrying values of remaining assets have been adequately stress-tested — to assess whether this is a clean reset or a lagging recognition of structural value erosion.

2. North America's margin compression warrants attention. Revenue in North America dipped to NZD 39.3m from NZD 40.1m and the EBITDA margin fell to approximately 23.4% from approximately 25.7%. Given that the impairment is most plausibly linked to North American carrying values, a simultaneous revenue decline and margin compression in that region is the operative signal behind the write-down. The company's stated strategic focus on ANZ expansion (the headline phrase "focused ANZ market expansion") implies a de-prioritisation of North America — but the region still contributes ~29.6% of group revenue. Any further deterioration there would affect both earnings and the adequacy of the current impairment level.

3. Cash generation improvement is genuine and the balance sheet is de-leveraging. OCF/EBITDA conversion improved to 89.5% from 59.2%, capex rose but is funding growth (now 12.5% of revenue), and free cash flow reached NZD 6.2m versus near-zero a year ago. Net debt/EBITDA at 0.3x gives the company meaningful strategic flexibility. These are durable improvements that stand separately from the impairment distortion.

Expectations

No formal guidance target or quantitative forward work figure was disclosed in the period. The basis for expectations assessment is therefore limited to trajectory and seasonality context.

The FY25 full-year result showed the business split roughly evenly between halves on revenue and EBITDA — HY25 was 49.3% of full-year revenue and 49.0% of EBITDA. On that basis, annualised HY26 revenue implies approximately NZD 198.2m for FY26, modestly ahead of the FY25 anchor of NZD 194.4m.

The revenue growth rate of 3.3% in HY26 is below the 8% growth achieved in HY25. Whether this reflects market saturation in North America, a deliberate re-weighting toward ANZ, or a maturing customer base is not determinable from the disclosures provided.

The strong free cash flow improvement — from NZD 0.1m to NZD 6.2m — is consistent with the company's multi-period narrative of building toward sustainable positive FCF. The 4G upgrade program that previously suppressed FCF appears substantially complete, removing a major drag. That said, capex rose NZD 3.3m half-on-half, and the sustainability of the FCF improvement depends on whether this capex step-up is temporary or marks a new base.

Quality of result

The cash-generative elements of the result are solid: operating cash flow of NZD 25.7m on EBITDA of NZD 28.7m represents conversion of 89.5%, well above the 59.2% achieved in HY25. This improvement reflects the post-4G-upgrade reduction in capitalised hardware spend flowing through operating cash rather than any working capital manipulation — receivable days moved only marginally to 65 days from 63 days.

The EBITDA margin compression (NZD 28.7m on NZD 99.1m revenue implies ~29.0%, versus ~30.4% in HY25) is a modest but real deterioration, suggesting cost growth is modestly outpacing revenue growth. Whether this is investment-phase overhead or structural cost creep is unclear without a detailed cost breakdown.

The reported NPAT of -NZD 144.2m is almost entirely non-cash and impairment-driven; it does not reflect the cash economics of the business in HY26. PBT is the cleaner measure and, even then, -NZD 136.6m is dominated by the impairment. Stripping that charge, the underlying pre-tax result would be approximately breakeven to slightly positive — consistent with the prior period's NZD -0.1m PBT. On that basis, the underlying trading quality has not materially improved at the pre-tax level despite higher revenue.

The tax line adds further distortion: an effective rate of ~5.6% on a large pre-tax loss, compared to a prior-period rate that is not meaningful given near-zero PBT.

Unresolved

• Impairment disclosure gap. The filing excerpt does not specify which assets were impaired, the triggering event, the recoverable amount methodology, or whether any sensitivity analysis was conducted on remaining goodwill. Until these disclosures are available, it is not possible to assess whether the write-down is conservative or whether further impairment risk remains.
• North America strategic direction. The pivot language toward "focused ANZ market expansion" is unquantified. Investors cannot determine whether North America will be harvested for cash, managed for stability, or further written down, and what the revenue and EBITDA profile of North America looks like on a standalone basis beyond the segment figures.
• EBITDA margin trajectory. With EBITDA falling NZD 0.5m on NZD 3.2m additional revenue, the incremental EBITDA margin was negative. Whether this reflects enterprise customer investment costs, stepped-up headcount, or one-off items within cost of revenue is not disclosed.
• Free cash flow definition. The release references both NZD 6.2m (free cash flow to the firm) and a separate NZD 5.1m figure; the reconciliation between these definitions is not fully transparent in the available data.

This briefing cannot assess the adequacy or completeness of the impairment charge without access to the full goodwill impairment note and the assumptions underpinning recoverable amount calculations.

Key metrics

Segment breakdown

Analytical metrics

---

This analysis was generated using Annolyse, an AI-powered tool that extracts and analyses NZX/ASX company announcements. The underlying data is extracted from official company filings and verified against source documents. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.